Clinical trial · Observational
Bone Geometry and Muscle Density Changes in Postmenopausal Women and Breast Cancer Patients Prescribed Anastrozole
NCT00421447CI-TRIAL-00019182completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of this study is to determine if trabecular or cortical volumetric bone mineral density (vBMD) change over time in postmenopausal breast cancer patients who are prescribed Anastrozole, as measured by pQCT at the proximal and distal radius and tibia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anastrozole | Drug | Anastrozole | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- Breast Cancer patients
- description
- A group of women with breast cancer prescribed Anastrozole
- interventionNames
- Drug: Anastrozole
- label
- Healthy women wit no breast Cancer
- description
- A group of healthy women wit no breast cancer prescribed Anastrozole
- interventionNames
- Drug: Anastrozole
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: Group 1: Treatment Group * Postmenopausal breast cancer patients (stage 1 and 2) * Non-institutionalized * Prescribed Anastrozole within the preceding 1-2 weeks * Ambulatory * Ability to read and comprehend study protocol and informed consent Group 2: Control Group * Healthy, age-matched postmenopausal women * Non-institutionalized * Ambulatory * Ability to read and comprehend study protocol and informed consent Exclusion Criteria: * Prior Tamoxifen or Raloxifene therapy * Known congenital metabolic bone disease (e.g., osteogenesis imperfecta) * Concomitant treatment with corticosteroids * Patients with a history of endocrine disorders or surgical parathyroidectomy * Patients with disorders known to affect bone metabolism including diabetes mellitus, systemic lupus erythematosus, Cushing's disease, hyperparathyroidism, chronic liver disease, chronic renal failure, Paget's disease * Conditions preventing pQCT measurement (e.g., unable to lie flat or still for 15 minutes) * Geographically inaccessible for follow-up
References
Publications (0)
Data not yet available
No reference posted for this study.